More than five years after the rollout of COVID-19 vaccines, the scientific community is gaining greater insights into their long-term safety.
New findings from a large, real-world study offer reassuring evidence: the Pfizer-BioNTech COVID-19 vaccine continues to demonstrate a strong and consistent safety profile years after individuals received their first vaccine.
Recently published in the journal Respiratory Medicine, “Long-term safety of the Pfizer-BioNTech COVID-19 vaccine: Results from the HERO-together study highlights data and analysis from HERO-Together, a patient-centered research initiative designed to examine potential side effects and hospitalizations reported by participants after receiving a COVID-19 vaccine.
Researchers examined safety outcomes over 24 months using a participant-facing portal, with a focus on identifying any emerging concerns over time and side effects that resulted in hospitalizations.
The analysis found no new safety issues associated with the vaccine. Results were consistent across demographic and clinical subgroups, emphasizing the vaccine’s safety in a real-world setting.
“I think what is most reassuring is just how consistent the results of the study were across subgroups, and how well they align with other studies showing long-term safety,” said Emily O’Brien, PhD, principal investigator and first author, and co-director of Population Health Sciences at the Duke Clinical Research Institute (DCRI). “The results of the study contribute to the growing body of research that demonstrates sustained safety of the vaccine years later.”
HERO-Together was part of the HERO Program, which was coordinated by the DCRI and part of a broader effort to understand long-term outcomes associated COVID-19 vaccinations. By leveraging patient-reported data and longitudinal follow-up, the program aimed to provide a more comprehensive view of safety and effectiveness in real-life settings.
These findings align with earlier research that demonstrated COVID-19 vaccine safety and provide greater confidence in the vaccine for future clinical and public health decision-making.